Skip to Content

Clinical Trials Detail

Celgene RV-AML-PI - 0759: Sequential Treatment with Azacitidine and Lenalidomide for Relapsed and Refractory Patients with Acute Myeloid Leukemia

Objective
This is a Phase 2 clinical study investigating the sequential use of azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia
IRB Protocol Number
12-1283
Principal Investigator(s)
DAN POLLYEA

Cancer Trials

  • Leukemia/Myelodysplasia
Sponsor(s)
UCCC
Contact
LEIGH WALZER at 720-848-0736
or LEIGH.WALZER@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : The amount of time you participate in this study will depend on how your disease responds and how you tolerate the treatment. After you stop study treatment, you will be asked to come to the clinic for a final visit. // Eligibility includes but is not limited to patients 18 years of age or older with relapsed and refractory acute myeloid leukemia